Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 16/20 | 0.60 |
| ▸ | JAK2 | O60674 | 14/20 | 0.60 |
| ▸ | HPGDS | O60760 | 1/20 | 0.54 |
| ▸ | JAK3 | P52333 | 9/20 | 0.46 |
| ▸ | TYK2 | P29597 | 2/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | PRKCA | P17252 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1717444 | 1.00 | JAK1 (0.60) | JAK1JAK2HPGDSJAK3TYK2 | |
| SCHEMBL1718163 | 0.99 | JAK1 (0.60) | JAK1JAK2HPGDSJAK3TYK2 | |
| SCHEMBL10125424 | 0.86 | JAK1 (0.47) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL2105053 | 0.86 | JAK1 (0.60) | JAK1JAK2HPGDSJAK3AURKA | |
| SCHEMBL12347953 | 0.84 | JAK1 (0.49) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL1934804 | 0.83 | JAK2 (0.60) | JAK1JAK2HPGDSJAK3TYK2 | |
| SCHEMBL15203406 | 0.83 | JAK1 (0.60) | JAK1JAK2HPGDSJAK3AURKA | |
| SCHEMBL30173286 | 0.82 | JAK1 (0.59) | JAK1JAK2HPGDSJAK3TYK2 | |
| SCHEMBL28608390 | 0.82 | JAK1 (0.59) | JAK1JAK2HPGDSJAK3TYK2 | |
| SCHEMBL14494043 | 0.81 | JAK1 (0.66) | JAK1JAK2HPGDSJAK3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921376-B2 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921376-B2 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-12-30 | — | — | US | disclosed |
| EP-1881983-B1 | PYRROLOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASE | VERTEX PHARMA (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2007-06-14 | — | — | US | disclosed |
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | JAK2, JAK1, JAK3 | JAK1 2/4885JAK2 1/4885HPGDS 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.